Hirakata, Japan

Hirofumi Arimura

This inventor holds 1 USPTO granted patent. Top assignee: Japanese Research and Development Association for Improvement of Enzyme. Active years: 1993.


% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1993

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hirofumi Arimura: Innovator in Enzyme Research

Introduction

Hirofumi Arimura is a notable inventor based in Hirakata, Japan. He has made significant contributions to the field of enzyme research, particularly in the development of alkaline proteases. His work has implications for various applications in biotechnology and industry.

Latest Patents

Hirofumi Arimura holds a patent related to alkaline protease, which includes an alkaline protease gene, recombinant DNA, and a DNA fragment. This patent describes an alkaline protease that has leucine or isoleucine in place of valine at the amino acid number 40 of the wild type alkaline protease. The patent also covers a gene encoding the amino acid sequence of alkaline protease with the aforementioned substitution, a recombinant DNA comprising said gene, and a method for producing the described alkaline protease.

Career Highlights

Arimura is associated with the Japanese Research and Development Association for Improvement of Enzyme. His work at this organization has allowed him to focus on innovative enzyme technologies and their applications in various fields.

Collaborations

Throughout his career, Hirofumi has collaborated with esteemed colleagues such as Eiichi Nakano and Yutaka Ishida. These collaborations have furthered research and development in enzyme technology.

Conclusion

Hirofumi Arimura's contributions to enzyme research, particularly through his patent on alkaline protease, highlight his role as an innovator in the field. His work continues to influence advancements in biotechnology and related industries.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…